For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of GLP-1/amylin agonist amycretin that achieved reductions of between 10.4% and 13.1% in ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Chief Executive David Ricks said the quarter was marked by robust sales for Zepbound and Mounjaro, in addition to momentum across other key medicines. Eli Lilly logged net income of $5.66 billion, or ...

Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...

Eli Lilly’s potential obesity pill helped patients lose less weight than investors had hoped during a trial, sending shares in the drugmaker down as much as 12 per cent in pre-market trading.